Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study

dc.contributor.authorMenéndez, Rosario
dc.contributor.authorMéndez, Raúl
dc.contributor.authorPolverino, Eva
dc.contributor.authorRosales Mayor, Edmundo
dc.contributor.authorAmara Elori, Isabel
dc.contributor.authorReyes, Soledad
dc.contributor.authorPosadas, Tomás
dc.contributor.authorFernández Barat, Laia
dc.contributor.authorTorres Martí, Antoni
dc.date.accessioned2018-06-15T13:15:16Z
dc.date.available2018-06-15T13:15:16Z
dc.date.issued2017-09-30
dc.date.updated2018-06-15T13:15:16Z
dc.description.abstractBackground: Bronchiectasis (BE) is a chronic structural lung disease with frequent exacerbations, some of which require hospital admission though no clear associated factors have been identified. We aimed to evaluate factors associated with hospitalization due to exacerbations during a 1-year follow-up period. Methods: A prospective observational study was performed in patients recruited from specialized BE clinics. We considered all exacerbations diagnosed and treated with antibiotics during a follow-up period of 1 year. The protocol recorded baseline variables, usual treatments, Bronchiectasis Severity Index (BSI) and FACED scores, comorbid conditions and prior hospitalizations. Results: Two hundred and 65 patients were recruited, of whom 162 required hospital admission during the follow-up period. Independent risk factors for hospital admission were age, previous hospitalization due to BE, use of proton pump inhibitors, heart failure, FACED and BSI, whereas pneumococcal vaccination was a protective factor. The area under the receiver operator characteristic curve (AUC) was 0.799 for BSI model was 0.799, and 0.813 for FACED model. Conclusions: Previous hospitalization, use of proton pump inhibitors, heart failure along with BSI or FACED scores is associated factors for developing exacerbations that require hospitalization. Pneumococcal vaccination was protective. This information may be useful for the design of preventive strategies and more intensive follow-up plans.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec675119
dc.identifier.issn1465-993X
dc.identifier.pmid28964260
dc.identifier.urihttps://hdl.handle.net/2445/123000
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12931-017-0659-x
dc.relation.ispartofRespiratory Research, 2017, vol. 18, num. 176
dc.relation.urihttps://doi.org/10.1186/s12931-017-0659-x
dc.rightscc-by (c) Menéndez, Rosario et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties pulmonars obstructives cròniques
dc.subject.classificationFactors de risc en les malalties
dc.subject.classificationVacuna antipneumocòccica
dc.subject.otherChronic obstructive pulmonary diseases
dc.subject.otherRisk factors in diseases
dc.subject.otherPneumococcal vaccine
dc.titleFactors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
675119.pdf
Mida:
614.8 KB
Format:
Adobe Portable Document Format